Oramed Pharmaceuticals, Inc. Share Price Xetra
Equities
OJU
US68403P1049
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
|
06-26 | Oramed Pharmaceuticals Board Approves $20 Million Share-Buyback Program | MT |
06-26 | Oramed Pharmaceuticals Inc. announces an Equity Buyback for $20 million worth of its shares. | CI |
Sales 2024 * | 750K 686K 57.67M | Sales 2025 * | 2M 1.83M 154M | Capitalization | 104M 95.15M 8B |
---|---|---|---|---|---|
Net income 2024 * | - 0 0 | Net income 2025 * | -14M -12.81M -1.08B | EV / Sales 2024 * | 139 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 52 x |
P/E ratio 2024 * |
-256
x | P/E ratio 2025 * |
-7.76
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.51% |
Managers | Title | Age | Since |
---|---|---|---|
Miriam Kidron
FOU | Founder | 83 | 11/04/02 |
Nadav Kidron
CEO | Chief Executive Officer | 50 | 11/04/02 |
Joshua Hexter
COO | Chief Operating Officer | 53 | 13/04/13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nadav Kidron
CEO | Chief Executive Officer | 50 | 11/04/02 |
Miriam Kidron
FOU | Founder | 83 | 11/04/02 |
Leonard Sank
BRD | Director/Board Member | 59 | 22/10/07 |
1st Jan change | Capi. | |
---|---|---|
+21.99% | 47.96B | |
+0.92% | 42.45B | |
+43.96% | 41.47B | |
+26.45% | 31.6B | |
+20.93% | 28.63B | |
-4.47% | 28.03B | |
+52.26% | 14.56B | |
+45.20% | 14.14B | |
+2.82% | 12.58B |
- Stock Market
- Equities
- ORMP Stock
- OJU Stock